GlassScriptPhysician profile
Caitlin Conlon
NPI 1003572579
$2,441.60
in general payments reported to CMS, 2019-2025
29 companies · $57.14 in 2025
The $57.14 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $1,047 · 2023: $728 · 2024: $484 · 2025: $57.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.82 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $293.66 | 2021-2024 | Bodyguardian |
| Abbvie INC. | $221.87 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.61 | 2022-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $205.32 | 2023 | Shingrix, Arexvy, Bexsero |
| Neurocrine Biosciences, INC. | $173.88 | 2022 | |
| Novo Nordisk INC | $167.01 | 2022-2024 | Rybelsus, Ozempic |
| Edwards Lifesciences Corporation | $142.73 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.96 | 2022-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Myovant Sciences INC. | $121.32 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $109.93 | 2022 | |
| Scynexis, INC. | $83.34 | 2022 | |
| Mallinckrodt Hospital Products INC. | $77.53 | 2023-2024 | Acthar |
| Lilly USA, LLC | $68.52 | 2022-2023 | Emgality, Jardiance |
| Dynavax Technologies Corporation | $61.47 | 2022-2023 | Heplisav-B |
| Ucb, INC. | $46.77 | 2024 | Cimzia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $37.68 | 2024 | Esophyx |
| Phadia US INC. | $36.38 | 2023 | Immunocap |
| Hologic Sales and Service, LLC | $31.01 | 2022 | |
| Sun Pharmaceutical Industries INC. | $25.04 | 2024 | |
| Electromed, INC. | $24.91 | 2024 | Smartvest |
| Medicure Pharma INC. | $22.17 | 2022 | |
| Merck Sharp & Dohme LLC | $21.92 | 2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Gilead Sciences, INC. | $20.35 | 2023 | |
| Mayne Pharma Commercial LLC | $18.05 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.36 | 2023 | Gvoke Hypopen |
| Eisai INC. | $16.64 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.63 | 2022 | |
| Octapharma USA, INC. | $15.07 | 2024 | Octagam Immune Globulin (Human) |
| Linus Health, INC. | $13.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Conlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.